ArticleInternational journal of clinical and experimental pathology2019
Clinical characteristics and prognostic analysis of ipsilateral supraclavicular lymph node metastases in breast cancer patients: a retrospective study.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Correlation between Baseline Conventional Ultrasounds, Shear-Wave Elastography Indicators, and Neoadjuvant Therapy Efficacy in Triple-Negative Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Article
- Integration the biologic factors into the staging of breast cancer patients with ipsilateral supraclavicular lymph node metastasis.Journal of Cancer · 2020Article
- Combined Therapy Can Improve the Outcomes of Breast Cancer with Isolated Supraclavicular Lymph Node Involvement.Cancer management and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the clinical characteristics and prognosis of different subtype breast cancer patients with pathologically proven ipsilateral supraclavicular lymph node metastasis (ISCLM).
methodsWe performed a retrospective analysis of clinical data for total 156 patients who diagnosed with ISCLM, among 3,133 breast cancer patients. Breast cancer subtypes were classified as hormone receptor (HR) positive (+)/human epidermal growth factor receptor 2 (HER2) negative (-), HR+/HER2+, HR-/HER2+ and triple-negative breast cancer (TNBC) subtypes using immunohistochemical staining. We subsequently analyzed matched cohorts, evaluating clinical features and survival in different subtypes.
resultsThe patients in this study accounted for 5% of all breast cancer patients treated during the same period. Breast cancer subtypes were confirmed in all 156 patients (39.7% with HR+/HER2-, 23.7% with HR+/HER2+, 14.7% with HR-/HER2+, and 21.8% with TNBC). The median overall survival after ISCLM was 47 months (95% confidence interval (CI), 3-94 months), and the overall 1-, 3- and 5-year survival rates were 92.3, 73.7 and 48.1%, respectively. We found that the survival rate is impacted by breast cancer subtypes (
conclusionsClinical breast cancer subtypes were still independent prognostic predictors among breast cancer patients with ISCLM. ISCLM arising from TNBC has the worst prognosis. Multidisciplinary therapy is beneficial for breast cancer patients with ISCLM.
Indexed as
Identifiers
31934200PMC6949811What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.